BioHarvest Sciences Reports First Quarter 2024 Financial Results

Q1 2024 Revenue Increased 147% Year-over-Year to US$5.34 Million Exceeding Previous Guidance Management Expects Q2 2024 Revenue in the Range of US$5.7-6.0 MillionVancouver, British Columbia and Rehovo

newsfileMay 30 08:30 ET

BioHarvest Sciences Sees Q1 Revenue Surge Above Guidance on Strong VINIA Sales | CSE:BHSC, OTC:CNVCF

Proactive InvestorsMay 30 06:14 ET

BioHarvest Sciences to Host Corporate Update Call May 2 at 2:30 P.M. Eastern Time

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - May 1, 2024) - BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) ("BioHarvest" or the "Company"), a biotechnology company pioneerin

newsfileMay 1 09:15 ET

BioHarvest Sciences Reports Fourth Quarter and Full Year 2023 Financial Results

FY 2023 Revenue Increased 2.3x to $12.7 Million USDThe Company expects Q1 2024 Revenue to be in the range of $5.2 million to $5.3 million and is providing Q2 2024 Revenue Guidance of $5.7-$6.0 million

newsfileApr 30 08:00 ET

BioHarvest Plans Nasdaq Uplisting After Successful Year of Sales Growth | CSE:BHSC, OTC:CNVCF

Proactive InvestorsApr 30 05:28 ET

BioHarvest Sciences Secures New State of the Art 80,0000 Square Foot Manufacturing Facility | CSE:BHSC, OTC:CNVCF

Proactive InvestorsApr 17 11:15 ET